European Medicines Agency's Management Board nominates Guido Rasi as Executive Director

Executive Director to be appointed following hearing at European Parliament


The European Medicines Agency's (EMA's) Management Board has nominated Professor Guido Rasi as the Executive Director of the Agency. At an extraordinary session on 1 October, the Board selected Professor Rasi from a shortlist of candidates provided by the European Commission.

Professor Rasi has been invited to give a statement to the European Parliament's Committee on the Environment, Public Health and Food Safety (ENVI) on 13 October 2015. The appointment of the new Executive Director will only be made after this session.

An information sheet explaining the process for the appointment of the EMA Executive Director together with a photo and biography of Professor Rasi is available on

Following his nomination, Professor Rasi said, "I am honoured to have been nominated as EMA's Executive Director and am grateful for the opportunity to continue our efforts to make the Agency fit for the challenges ahead. I am enormously proud of the Agency and its network. Looking to the future, we must continue to meet patients' legitimate expectations for access to new and safe therapeutic options. This requires that the medicines authorisation process not only supports the early stages of research and development, but also strives to make the best possible use of real world data throughout a medicine's lifecycle."

Following Professor Rasi's nomination, the Chair of the Management Board, Professor Sir Kent Woods said, "The Management Board is pleased to announce the nomination of Guido Rasi as Executive Director of EMA. The decision of the Management Board is the result of a robust recruitment process over the last months. We look forward to Professor Rasi resuming his leadership of the Agency."

Deputy Executive Director Andreas Pott will continue to lead EMA operations and to legally represent the Agency until the new Executive Director has officially taken up his duties.


Suggested Articles

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.

Amid a tough fight in the blood thinner market, J&J and Bayer's Xarelto scored a trial win in treating PAD patients after a recent leg artery surgery.

Experts say it's worth exploring whether a Roche stroke drug could help certain COVID-19 patients.